Small Molecules

24 Jan 2021 Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
22 Jan 2021 ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
21 Jan 2021 FDA Grants Priority Review to Genentech’s Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease
20 Jan 2021 Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
20 Jan 2021 Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
20 Jan 2021 C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies
20 Jan 2021 Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement
20 Jan 2021 Terns Announces FDA Clearance of Investigational New Drug (IND) Application for First-in-Human Phase 1 Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH
20 Jan 2021 Apnimed Announces First Patient Dosed in a Second Phase 2 Clinical Trial with AD109, a Disease Modifying Candidate for Obstructive Sleep Apnea
20 Jan 2021 Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes
20 Jan 2021 Doptelet® (avatrombopag) approved in the EU for treatment of ITP
19 Jan 2021 Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
18 Jan 2021 Positive Phase 1 results in high-dose setanaxib trial
16 Jan 2021 Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
16 Jan 2021 Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer
15 Jan 2021 Dompé Announces First Patient Enrolled in Phase 3 trial of Ladarixin, an Oral Investigational CXCR1/2 Inhibitor, in New-Onset Type 1 Diabetes (T1D)
15 Jan 2021 Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis
15 Jan 2021 Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
13 Jan 2021 Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas
12 Jan 2021 Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
12 Jan 2021 Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
12 Jan 2021 U.S. FDA grants Priority Review to New Drug Application for finerenone to treat patients with chronic kidney disease and type 2 diabetes
12 Jan 2021 Beactica Therapeutics and University of Dundee announce collaboration to develop WRN inhibitors to target cancer
11 Jan 2021 IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA
11 Jan 2021 Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up